Electronic Communications with Shareholders

RNS Number : 0899R

Avacta Group PLC

03 March 2021

 

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Electronic Communications with Shareholders

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and reagents, announces that it has today posted a letter concerning electronic communications to its new shareholders that have become holders of ordinary shares in the Company since the last deemed consent letter was sent.

As part of Avacta's commitment to reducing the impact of its activities on the environment, whenever possible, the Company wishes to notify shareholders of its results and other news electronically.

The letter will be available on the Investors section of Company's website at www.avacta.com and sets out the actions to be taken by shareholders.

- Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc	Tel: [phone]
Alastair Smith, Chief Executive Officer	www.avacta.com
Tony Gardiner, Chief Financial Officer
finnCap Ltd (Nominated Adviser and Joint Broker)	Tel: [phone]
Geoff Nash / Giles Rolls - Corporate Finance Tim Redfern - ECM	www.finncap.com
Stifel Nicolaus Europe Limited (Joint Broker)	Tel: [phone]
Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison	www.stifel.com
FTI Consulting (Financial Media and IR)	Tel: [phone]
Simon Conway / Stephanie Cuthbert	[e-mail]
Zyme Communications (Trade and Regional Media)	Tel: [phone]
Katie Odgaard	[e-mail]

About Avacta Group plc - https://www.avacta.com

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer®biologics and pre|CISION™tumour targeted chemotherapies.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.

Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.

The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.

Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX™SARS-CoV-2 Lateral Flow Rapid Antigen Test and a BAMS™SARS-CoV-2 Assay in partnership with Adeptrix Inc.

Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Group is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Group's lead pre|CISION™prodrug, in patients with locally advanced or metastatic selected solid tumours.

Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with Moderna Therapeutics Inc., a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION™platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.

To register for news alerts by email go to  www.avacta.com/investor-news-email-alerts

 

END

 

 

NRAEAXDDEFAFEFA